Salvage treatment for recurrences after first resection of colorectal liver metastases: the impact of histopathological growth patterns.
Biomarker
Colorectal liver metastases
Histopathological growth patterns
Prognostication
Salvageable recurrences
Journal
Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
01
02
2019
accepted:
04
03
2019
pubmed:
8
3
2019
medline:
8
2
2020
entrez:
8
3
2019
Statut:
ppublish
Résumé
The majority of patients recur after resection of colorectal liver metastases (CRLM). Patients with CRLM displaying a desmoplastic histopathological growth pattern (dHGP) have a better prognosis and lower probability of recurrence than patients with non-dHGP CRLM. The current study evaluates the impact of HGP type on the pattern and treatment of recurrences after first resection of CRLM. A retrospective cohort study was performed, including patients with known HGP type after complete resection of CRLM. All patients were treated between 2000 and 2015. The HGP was determined on the CRLM resected at first partial hepatectomy. The prognostic value of HGPs, in terms of survival outcome, in the current patient cohort were previously published. In total 690 patients were included, of which 492 (71%) developed recurrent disease. CRLM displaying dHGP were observed in 103 patients (21%). Amongst patients with dHGP CRLM diagnosed with recurrent disease, more liver-limited recurrences were seen (43% vs. 31%, p = 0.030), whereas patients with non-dHGP more often recurred at multiple locations (34% vs. 19%, p = 0.005). Patients with dHGP CRLM were more likely to undergo curatively intended local treatment for recurrent disease (adjusted odds ratio: 2.37; 95% confidence interval (CI) [1.46-3.84]; p < 0.001) compared to patients with non-dHGP. The present study demonstrates that liver-limited disease recurrence after complete resection of CRLM is more often seen in patients with dHGP, whereas patients with non-dHGP more frequently experience multi-organ recurrence. Recurrences in patients with dHGP at first CRLM resection are more likely to be salvageable by local treatment modalities, but no prognostic impact of HGPs after salvage therapy for recurrent disease was found.
Identifiants
pubmed: 30843120
doi: 10.1007/s10585-019-09960-7
pii: 10.1007/s10585-019-09960-7
pmc: PMC6445820
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-118Références
Lancet Oncol. 2013 Nov;14(12):1208-15
pubmed: 24120480
Surgery. 2016 Feb;159(2):632-40
pubmed: 26477476
Ann Surg Oncol. 2012 Jan;19(1):139-44
pubmed: 21751045
Ann Surg Oncol. 2018 Aug;25(8):2457-2466
pubmed: 29786130
HPB (Oxford). 2011 Nov;13(11):774-82
pubmed: 21999590
Clin Exp Metastasis. 2015 Apr;32(4):369-81
pubmed: 25822899
BMC Cancer. 2014 Mar 11;14:174
pubmed: 24612620
Br J Surg. 2013 May;100(6):808-18
pubmed: 23494765
Ann Surg Oncol. 2011 May;18(5):1380-8
pubmed: 21136180
J Clin Oncol. 2007 Oct 10;25(29):4575-80
pubmed: 17925551
Ann Surg Oncol. 2014 Apr;21(4):1276-86
pubmed: 24346766
Clin Cancer Res. 2013 Aug 1;19(15):4104-13
pubmed: 23741067
Br J Cancer. 2017 Nov 7;117(10):1427-1441
pubmed: 28982110
Ann Surg. 2010 May;251(5):902-9
pubmed: 20395862
Ann Surg. 2009 Sep;250(3):440-8
pubmed: 19730175
Eur J Cancer. 2012 Aug;48(12):1757-65
pubmed: 22153217
Br J Surg. 2014 Dec;101(13):1681-91
pubmed: 25331841
Ann Surg. 2011 Feb;253(2):349-59
pubmed: 21178761
Mod Pathol. 2014 Dec;27(12):1641-8
pubmed: 24851832
J Gastrointest Surg. 2009 May;13(5):890-5
pubmed: 19132450
Ann Surg. 2017 Jan;265(1):158-165
pubmed: 28009741
Ann Surg Oncol. 2015 Aug;22(8):2761-71
pubmed: 25572686
Cancer. 2014 Aug 1;120(15):2316-24
pubmed: 24737664
Ann Surg. 2014 Mar;259(3):543-8
pubmed: 23732261
Eur J Surg Oncol. 2015 Jul;41(7):859-67
pubmed: 25979624
Nat Med. 2016 Nov;22(11):1294-1302
pubmed: 27748747
Clin Exp Metastasis. 2012 Aug;29(6):541-9
pubmed: 22476470
Eur J Surg Oncol. 2018 Oct;44(10):1610-1618
pubmed: 30115500
Ann Surg Oncol. 2016 Nov;23(12):3999-4007
pubmed: 27393572
HPB (Oxford). 2016 Mar;18(3):209-20
pubmed: 27017160
Eur J Cancer. 2014 Jul;50(10):1747-1757
pubmed: 24767470
J Natl Cancer Inst. 2014 Jun 12;106(7):
pubmed: 24925349
Clin Exp Metastasis. 2019 Aug;36(4):311-319
pubmed: 31134394
J Clin Oncol. 2017 Jun 10;35(17):1938-1944
pubmed: 28426374
Br J Surg. 2016 Jul;103(8):1055-62
pubmed: 27193207
J Pathol. 2001 Oct;195(3):336-42
pubmed: 11673831
Br J Surg. 2006 Apr;93(4):457-64
pubmed: 16555242
Medicine (Baltimore). 2016 Feb;95(8):e2924
pubmed: 26937938
Angiogenesis. 2019 May;22(2):355-368
pubmed: 30637550
JAMA Surg. 2018 Jul 18;153(7):e180996
pubmed: 29799910